Agenus (FRA:AJ8) Accounts Payable : €46.6 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Agenus Accounts Payable?

Agenus's Accounts Payable for the quarter that ended in Mar. 2024 was €46.6 Mil.

Agenus's quarterly Accounts Payable increased from Sep. 2023 (€38.3 Mil) to Dec. 2023 (€56.3 Mil) but then declined from Dec. 2023 (€56.3 Mil) to Mar. 2024 (€46.6 Mil).

Agenus's annual Accounts Payable increased from Dec. 2021 (€27.0 Mil) to Dec. 2022 (€38.6 Mil) and increased from Dec. 2022 (€38.6 Mil) to Dec. 2023 (€56.3 Mil).

Agenus Accounts Payable Historical Data

The historical data trend for Agenus's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Accounts Payable Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

12.21

13.99

26.98

38.65

56.35

Agenus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															43.68	48.43	38.30	56.35	46.64

Agenus Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Agenus Accounts Payable Related Terms

Thank you for viewing the detailed overview of Agenus's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Agenus (FRA:AJ8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

AGEN:USA AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines